On July 10, MicroPort MedBot-B rose 5.16% in regular trading, trading at HK$26.12/share, with turnover of approximately HK$61.51 million.

The rally was driven by continued market attention to the company's Toumai laparoscopic surgical robot completing its 200th commercial installation worldwide, recently deployed at Spain's top medical institution HM Hospitales. All 200 units have received acceptance reports from end customers. Additionally, Toumai's global commercial orders have surpassed 300 units, with first-half order volume already exceeding the full-year total of the prior year. The company has achieved commercial installations across more than 60 countries and regions, with particularly strong momentum in emerging markets including India, Brazil, and Argentina.

The broader Hong Kong-listed robotics concept sector has maintained strength in recent sessions, providing additional tailwind. Separately, the Toumai remote surgical robot recently became the first to obtain EU CE certification for remote surgery applications, further expanding its addressable market. Investment banks including CICC and Goldman Sachs maintain positive ratings on the stock, citing accelerating overseas revenue growth and narrowing losses.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)